Martin Shkreli's Phama Company Will Cut Price-Gouged Cost in Half (For Some)

Martin Shkreli, the Turing Pharmaceuticals founder who made headlines and earned the scorn of millions when he jacked up the price of an anti-parasite drug 5,000 percent, is again under attack. This time, though, it's for how little he's reducing the price of Duraprim, which is a critical and often lifesaving treatment for people living with HIV and others with compromised immune systems.

The drug, which once cost $13.50, now goes for $750 per pill, and the Wall Street Journal reported Friday that the price will soon be cut up to 50 percent -- but only for hospitals. And according to the Journal, the discount will depend on how much of the drug a hospital uses.

The Human Rights Campaign criticized Shkreli for limiting the "roll back" to hospitals and not consumers, and for not reducing the cost to anywhere near its original pricepoint.

"Martin Shkreli is not pulling the wool over anyone's eyes," said HRC President Chad Griffin in a statement posted online.

"After increasing the price of Daraprim by 5,000 percent, he now proposes to gouge critically ill people upwards of $375 for a drug that used to cost just a few dollars. His desire to turn a profit at any cost and brazen disregard for the well-being of the most vulnerable patients -- including people with HIV and pregnant women -- is appalling and contemptible."

Trending stories

Joe Biden has tied the record for most LGBTQ+ judges confirmed in federal courts

Watch: In gay period romance 'Lilies Not For Me,' playful wrestling turns sensual (exclusive)

Discover the power of Wellness in your life

JD Vance ruthlessly mocked after everyone in Greenland refused to welcome wife Usha Vance

'Mid-Century Modern': Celebrate Linda Lavin's most iconic roles

Bob the Drag Queen shades Mistress Isabelle Brooks’ weight loss: 'Girl, you have to get new pads'

France becomes world’s first country to enshrine abortion rights in constitution

Where to stay in LGBTQ+ Ireland: Castles, domes and luxury retreats

Trump's orders prompt CDC to erase HIV resources

Elon Musk uses burner accounts on X, doesn’t fact-check: report

Matt Bomer, as a 'Mid-Century Modern' ditz, can finally 'experience queer joy'

The Charles is Pacific Grove's new LGBTQ+ hotel

Nathan Lee Graham wants 'Mid-Century Modern's queer viewers to 'lean into the joy'

Alan Cumming jumps for joy after major 'Avengers: Doomsday' casting news

Gerald Garth is keeping people of color happy and healthy through trying times

Season 4 of The Switch on resilience & radical self-love returns this spring

How climate disasters hurt mental health in young people

In 'Mid-Century Modern,' the 'gay Avengers' assemble for needed comic relief

Discover why chic Costa Navarino is Europe's luxury getaway

SFAF's Dr. Tyler TerMeer says he'll continue to fight for health care for all

Cowboys & Queens U.S. tour by Jane Hilton: A modern American dream

In 'Survival of the Thickest,' queer joy and activism are one and the same

From rock legends to Pride flags: Discover the vibrant LGBTQ+ scene in Asbury Park

All 6 rogue Mississippi cops got long prison sentences in 'Goon Squad' torture of 2 Black men

​6 lesbian films coming we can't wait to see in 2025

• 0
• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8

Turing remains under investigation by New York Attorney General Eric Schneiderman for possibly violating antitrust laws by limiting distribution of a drug that is essential to the lives of medically vulnerable people. The Senate has also launched a bipartisan investigation into the matter.

As explained to The Advocate by infectious disease specialist Dr. Kalvin Yu, who is currently the chief integration officer at Kaiser Permanente Southern California, Duraprim is the cornerstone component of a combination of two or three drugs used to treat toxoplasmosis, an infection in the brain that can cause blindness, seizures, and neurologic deficits in movement. It is acquired by ingesting the toxoplasmosis organism via undercooked meat and contamination with cat feces. People with immune system deficiencies and pregnant women are particularly at risk.

Shkreli declined to comment about the change in price when contacted by the Business Insider website.